Clinical trialsOfficial

Health Canada lists Type II recall of KayserBett IDA paediatric care beds

🇨🇦 Health Canada · Wed 04 Nov 2026

Kayserbetten has assessed that IDA beds sold in Canada carry an injury risk comparable to a serious incident abroad, tied to hand control locking instructions.

Health Canada has published a Type II recall for the KayserBett IDA paediatric care bed, made by Kayserbetten GmbH & Co KG of Bad Fallingbostel, Germany. The notice, identified as RA-82903, was published on 4 November 2026 and gives a recall date of 30 April 2026. It is categorised under general hospital and personal use medical devices, with the issue described as performance-related.

The recall follows a serious incident involving a KayserBett IDA bed, model OLAF, sold outside Canada. Kayserbetten carried out a comprehensive risk assessment and concluded that the IDA model marketed in Canada presents a comparable injury risk. The source does not describe the incident itself or the nature of any injury.

According to the notice, the risk arises solely from failure to follow the documented safety instructions for locking the hand control after use. Two models are affected, IDA-1 and IDA-2. For each, the listing says there are more than 10 lot or serial numbers and directs readers to the manufacturer for the full list.

The only action stated is that anyone needing further information should contact the manufacturer. The notice does not set out corrective measures, the number of units affected or distribution details. In general, Health Canada uses Type II for recalls where use of a product may cause temporary or medically reversible health effects, or where the likelihood of serious harm is remote.

What it means for your team

  • Quality and regulatory teams supplying or maintaining IDA-1 or IDA-2 beds in Canada should contact Kayserbetten for the complete lot and serial number list.
  • Post-market surveillance teams may note the cross-market link: an incident with a non-Canadian model (OLAF) triggered a risk assessment of the Canadian model.
  • The stated risk relates to adherence to documented instructions on locking the hand control after use, which may be relevant to user information and training reviews.
  • The notice gives no details on corrective actions or affected quantities, so further information must come from the manufacturer.

Official source: Health Canada ↗

Article written by VigiEye from the official source (Health Canada). AI-assisted; check the source before acting.

More Clinical trials All →